We are happy to share with you our latest publication on time-to-event outcomes in patients with nonmetastatic castration-resistant prostate cancer (NM-CRPC). For these patients, currently, no effective treatments resulting in longer survival compared with watchful waiting are available. On average, without additional treatment, half of these patients survive around 45 months after NM-CRPC diagnosis.

 Interested? Click here or contact us!